跳至主要内容
临床试验/CTRI/2024/12/077994
CTRI/2024/12/077994已完成不适用

Intermittent versus daily vitamin D supplementation in children with chronic kidney disease stages 3 to 5 – A Non-Inferiority Trial

Pujitha Vallabhaneni1 个研究点 分布在 1 个国家目标入组 234 人开始时间: 2024年12月23日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
234
试验地点
1
主要终点
Compare 25 hydroxy vitamin D levels

研究概览

简要总结

This is a single-center, open-label, randomized controlled non-inferiority trial aims to compare the efficacy and safety of monthly versus daily vitamin D supplementation in children aged 1 to 14 years with chronic kidney disease (CKD) stages 3–5. The study will recruit 234 participants with baseline serum vitamin D levels between 12–50 ng/mL and an eGFR < 60 mL/1.73 m²/hr. Participants will be randomized into two groups: one receiving monthly cholecalciferol (60,000 IU) and the other receiving daily cholecalciferol (2,000 IU) for six months. The primary objective is to compare 25-hydroxyvitamin D (25OHD) levels at 3 and 6 months. Secondary objectives include assessing serum calcium, phosphate, intact parathyroid hormone (iPTH), bone turnover markers (bone-specific alkaline phosphatase, TRACP-5b, CTX-I), and bone mineral density (BMD) via DEXA at baseline and 6 months. Routine biochemical tests, including serum electrolytes, creatinine, eGFR, and urine calcium-creatinine ratio, will also be evaluated. Participants will be monitored for compliance, adverse events, and treatment-emergent complications. With sample sizes of 117 in Group A and 117 in Group B, the study is designed to achieve 80% power to detect non-inferiority using a one-sided, two-sample t-test. The margin of non-inferiority is set at -0.100. The assumed true difference between the means is 5.500. The significance level (alpha) of the test is 0.05. The sample size was calculated from study populations with standard deviations of 18.910 and 15.130. Statistical analyses will be conducted using SPSS version 26.0. Descriptive statistics will be utilized to summarize demographic data, medical diagnoses, and clinical characteristics of the patients. Categorical variables will be expressed as frequency (percentage), while continuous variables will be presented as mean ± standard deviation (SD) or median and interquartile range (IQR) as appropriate. Associations between qualitative variables will be assessed using the chi-square test or Fisher’s exact test. The normality of continuous variables will be evaluated using the Shapiro-Wilk test, and accordingly, the Student’s t-test or Mann-Whitney U test will be applied.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
12.00 Month(s) 至 14.00 Year(s)(—)
性别
All

入选标准

  • Age 1 to 14 years CKD with eGFR less than 60ml/1.73m2/hr Children with vitamin D levels between 12 to 50ng/ml Patient willing to give written informed consent.

排除标准

  • •Vitamin D levels of more than 100ng/ml or hypercalciuria or nephrocalcinosis or hypercalcemia, or suppressed iPTH •Not willing to come for follow-up at 3 months and 6 months.

结局指标

主要结局

Compare 25 hydroxy vitamin D levels

时间窗: Baseline, 12 weeks, 24 weeks

次要结局

  • Level of serum calcium, phosphate, iPTH(Baseline, 12 weeks, 24 weeks)
  • Urine spot calcium creatinine ratio, USG KUB for nephrocalcinosis(baseline, 24 weeks)
  • Estimated GFR(Baseline, 12week, 24 weeks)
  • Level of BSALP TRACP-5b CTX – I(Baseline, 24 week)
  • Bone mineral density measured by DEXA(Baseline, 24 weeks)

研究者

发起方
Pujitha Vallabhaneni
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Lesa Dawman

PGIMER Chandigarh

研究点 (1)

Loading locations...

相似试验

Assess the effect of Monthly versus daily vitamin D... | 临床试验